Experimental Novartis radiopharma drug shows promise in early study

FierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3

Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times

Endpoints NewsParabilis Medicines charts $413M IPO to back peptide pipeline

FierceBiotechInnovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC

PharmaVoiceHouse bill aims to crack down on China biotech deals

PharmaVoicePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

FierceBiotechMedline earns FDA warning letter ire for repeated toxic bacteria problems

FierceBiotechFrom business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’

BioWorldFDA clears Shionogi’s Xocova as first COVID-19 prevention pill

BrukerBruker showcases expanded microbiology diagnostics portfolio - Investing.com

BrukerBruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026 - 巴士的報